News Novartis builds in cardiovascular with $3.1bn Anthos buy Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Oncology World Thrombosis Day at 10, talking blood clots and cancer A new 'Move Against Thrombosis' campaign and discussion of cancer-related blood clotting.
Market Access New FDA head says no more pharma on advisory committees The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl